10:10:29 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-01-28 Bokslutskommuniké 2024
2024-10-24 Kvartalsrapport 2024-Q3
2024-07-12 Kvartalsrapport 2024-Q2
2024-04-26 Ordinarie utdelning XVIVO 0.00 SEK
2024-04-25 Årsstämma 2024
2024-04-24 Kvartalsrapport 2024-Q1
2024-01-25 Bokslutskommuniké 2023
2023-10-24 Kvartalsrapport 2023-Q3
2023-07-13 Kvartalsrapport 2023-Q2
2023-04-26 Ordinarie utdelning XVIVO 0.00 SEK
2023-04-25 Årsstämma 2023
2023-04-24 Kvartalsrapport 2023-Q1
2023-01-26 Bokslutskommuniké 2022
2022-10-27 Kvartalsrapport 2022-Q3
2022-07-13 Kvartalsrapport 2022-Q2
2022-04-27 Ordinarie utdelning XVIVO 0.00 SEK
2022-04-26 Årsstämma 2022
2022-04-25 Kvartalsrapport 2022-Q1
2022-01-27 Bokslutskommuniké 2021
2021-10-28 Kvartalsrapport 2021-Q3
2021-07-13 Kvartalsrapport 2021-Q2
2021-04-23 Ordinarie utdelning XVIVO 0.00 SEK
2021-04-22 Årsstämma 2021
2021-04-21 Kvartalsrapport 2021-Q1
2021-01-28 Bokslutskommuniké 2020
2020-10-23 Kvartalsrapport 2020-Q3
2020-10-14 Extra Bolagsstämma 2020
2020-07-10 Kvartalsrapport 2020-Q2
2020-04-09 Kvartalsrapport 2020-Q1
2020-04-01 Ordinarie utdelning XVIVO 0.00 SEK
2020-03-31 Årsstämma 2020
2020-01-30 Bokslutskommuniké 2019
2019-10-24 Kvartalsrapport 2019-Q3
2019-07-12 Kvartalsrapport 2019-Q2
2019-04-26 Ordinarie utdelning XVIVO 0.00 SEK
2019-04-25 Årsstämma 2019
2019-04-24 Kvartalsrapport 2019-Q1
2019-02-08 Bokslutskommuniké 2018
2018-10-26 Kvartalsrapport 2018-Q3
2018-07-13 Kvartalsrapport 2018-Q2
2018-04-30 Ordinarie utdelning XVIVO 0.00 SEK
2018-04-27 Årsstämma 2018
2018-04-26 Kvartalsrapport 2018-Q1
2018-02-09 Bokslutskommuniké 2017
2017-10-27 Kvartalsrapport 2017-Q3
2017-07-14 Kvartalsrapport 2017-Q2
2017-04-27 Ordinarie utdelning XVIVO 0.00 SEK
2017-04-26 Årsstämma 2017
2017-04-25 Kvartalsrapport 2017-Q1
2017-04-10 Extra Bolagsstämma 2017
2017-02-08 Bokslutskommuniké 2016
2016-10-27 Kvartalsrapport 2016-Q3
2016-07-15 Kvartalsrapport 2016-Q2
2016-05-04 Ordinarie utdelning XVIVO 0.00 SEK
2016-05-03 Årsstämma 2016
2016-04-26 Kvartalsrapport 2016-Q1
2016-02-04 Bokslutskommuniké 2015
2015-10-23 Kvartalsrapport 2015-Q3
2015-08-13 Kvartalsrapport 2015-Q2
2015-04-24 Ordinarie utdelning XVIVO 0.00 SEK
2015-04-23 Årsstämma 2015
2015-04-22 Kvartalsrapport 2015-Q1
2015-02-05 Bokslutskommuniké 2014
2014-10-24 Kvartalsrapport 2014-Q3
2014-10-24 Analytiker möte 2014
2014-08-13 Kvartalsrapport 2014-Q2
2014-04-30 Ordinarie utdelning XVIVO 0.00 SEK
2014-04-29 Årsstämma 2014
2014-04-23 Kvartalsrapport 2014-Q1
2014-02-07 Bokslutskommuniké 2013
2013-11-07 Analytiker möte 2013
2013-11-07 Kvartalsrapport 2013-Q3
2013-07-11 Kvartalsrapport 2013-Q2
2013-05-08 Ordinarie utdelning XVIVO 0.00 SEK
2013-05-07 Årsstämma 2013
2013-04-19 Kvartalsrapport 2013-Q1
2013-02-19 Bokslutskommuniké 2012
2012-11-01 Kvartalsrapport 2012-Q3

Beskrivning

LandSverige
ListaMid Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
Xvivo Perfusion är verksamt inom medicinteknik. Bolaget tillhandahåller lösningar för transplantation av lungor. Exempel på produkter som bolaget levererar innefattar kanyler, organförvaring samt kyllösningar. Produkterna vidaresäljs till kliniker och forskningsinstitut runtom den globala marknaden, med störst närvaro inom Norden och Europa. Bolaget kom till via en avknoppning från Vitrolife under 2012 och har sitt huvudkontor i Göteborg.
2022-05-04 08:00:00

XVIVO is pleased to announce that Mayo Clinic in Florida and Northwestern Medicine in Illinois, USA, are the first to receive XVIVO’s Kidney Assist Transport. The device is a transportable organ perfusion system that allows for continuous oxygenated perfusion for up to 24 hours and has been shown to improve preservation compared to cold storage.

Today, the US is the largest kidney transplant market with approximately 18,700 transplants from deceased donors in 2021, and there are currently more than 90,000 patients on the waitlist for a new kidney. Thus, the need for organs available for transplantation far exceeds the supply. By introducing Kidney Assist Transport in the US, XVIVO brings innovation to the kidney market that has the potential to increase the number of kidney transplants significantly.
An article in the scientific journal The Lancet suggests that hypothermic machine perfusion with oxygen using Kidney Assist Transport can reduce severe complications, additional diagnostic procedures, hospital readmission and cost for chronic dialysis[1].

The Northwestern Medicine Organ Transplant Center is the largest and most successful transplant program in Illinois, performing 295 kidney transplants in 2021 and nearly 6,500 kidney transplants since its inception in 1964. The team aims to provide transplant options to all patients who suffer from kidney failure, including those who have complex medical issues.

“This technology will help us enhance the quality of transplanted kidneys, mainly because of continuous oxygenation during perfusion. We expect this to make even more donor kidneys viable for transplantation, which means more patients will receive the life-changing care they need,” says Dr. Daniel Borja-Cacho, transplant surgeon at Northwestern Medicine.

“We are extremely happy that two of the leading hospitals in the US are first with Kidney Assist Transport. Launching this technology on the world’s largest transplant market is very rewarding as our strategy is to become global leaders within abdominal transplantation. A new era for XVIVO has now begun” says Dag Andersson, CEO of XVIVO.

May 4, 2022
Gothenburg
Dag Andersson, CEO
XVIVO Perfusion AB (publ)


[1] Johmanns I, et al. Oxygenated versus standard cold perfusion preservation in kidney transplantation (COMPARE): a randomised, double-blind, paired, phase 3 trial. The Lancet. November 2020;396(10263):1653-1662